Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ENSC Ensysce Biosciences	$2.13 -1.4%	$2.21	$1.62 ▼ $14.67	$5.12M	0.98	951,334 shs	76,623 shs
FNCH Finch Therapeutics Group	$12.50	$13.22	$1.27 ▼ $15.85	$20.08M	1.21	2,097 shs	1,390 shs
RLMD Relmada Therapeutics	$0.58 -3.0%	$0.64	$0.24 ▼ $4.37	$19.75M	0.59	971,973 shs	214,781 shs
RVPH Reviva Pharmaceuticals	$0.40 -1.5%	$0.69	$0.30 ▼ $4.28	$19.45M	-0.06	1.46 million shs	1.55 million shs

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ENSC Ensysce Biosciences	-1.39%	-1.39%	0.00%	+21.02%	-69.66%
FNCH Finch Therapeutics Group	0.00%	-1.96%	-6.94%	-3.85%	+756.16%
RLMD Relmada Therapeutics	-3.04%	-5.41%	-17.56%	+99.10%	-84.49%
RVPH Reviva Pharmaceuticals	-1.51%	+2.02%	-40.79%	-48.99%	-66.60%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ENSC Ensysce Biosciences	0.5598 of 5 stars	0.0	4.0	0.0	1.8	0.0	0.6
FNCH Finch Therapeutics Group	0.7895 of 5 stars	0.0	5.0	0.0	0.0	1.7	0.6
RLMD Relmada Therapeutics	4.7588 of 5 stars	3.1	5.0	4.4	1.9	4.2	1.3
RVPH Reviva Pharmaceuticals	3.3842 of 5 stars	3.6	2.0	0.0	3.8	3.3	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ENSC Ensysce Biosciences	0.00	N/A	N/A	N/A
FNCH Finch Therapeutics Group	0.00	N/A	N/A	N/A
RLMD Relmada Therapeutics	2.25	Hold	$5.00	766.55% Upside
RVPH Reviva Pharmaceuticals	3.29	Buy	$9.00	2,155.07% Upside

Current Analyst Ratings Breakdown

Latest ENSC, RLMD, RVPH, and FNCH Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/27/2025	RVPH Reviva Pharmaceuticals	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$3.00
6/3/2025	RVPH Reviva Pharmaceuticals	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$3.00
5/20/2025	RVPH Reviva Pharmaceuticals	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$8.00 ➝ $3.00
4/24/2025	RVPH Reviva Pharmaceuticals	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$8.00 ➝ $8.00

(Data available from 7/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ENSC Ensysce Biosciences	$5.21M	0.97	N/A	N/A	$2.59 per share	0.82
FNCH Finch Therapeutics Group	N/A	N/A	N/A	N/A	$14.25 per share	N/A
RLMD Relmada Therapeutics	N/A	N/A	N/A	N/A	$1.18 per share	N/A
RVPH Reviva Pharmaceuticals	N/A	N/A	N/A	N/A	$0.02 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ENSC Ensysce Biosciences	-$7.99M	-$6.54	N/A	N/A	N/A	-109.49%	-192.54%	-121.77%	8/13/2025 (Estimated)
FNCH Finch Therapeutics Group	-$74.75M	-$8.82	N/A	∞	N/A	N/A	-69.14%	-26.92%	N/A
RLMD Relmada Therapeutics	-$79.98M	-$2.51	N/A	N/A	N/A	N/A	-181.26%	-151.23%	8/6/2025 (Estimated)
RVPH Reviva Pharmaceuticals	-$29.92M	-$0.79	N/A	N/A	N/A	N/A	N/A	-302.31%	8/13/2025 (Estimated)

Latest ENSC, RLMD, RVPH, and FNCH Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	Q2 2025	ENSC Ensysce Biosciences	-$1.02	N/A	N/A	N/A	$0.67 million	N/A
8/13/2025	Q2 2025	RVPH Reviva Pharmaceuticals	-$0.15	N/A	N/A	N/A	N/A	N/A
8/6/2025	Q2 2025	RLMD Relmada Therapeutics	-$0.25	N/A	N/A	N/A	N/A	N/A
5/15/2025	Q1 2025	RVPH Reviva Pharmaceuticals	-$0.21	-$0.13	+$0.08	-$0.13	N/A	N/A
5/13/2025	Q1 2025	ENSC Ensysce Biosciences	-$3.02	-$1.39	+$1.63	-$1.39	$0.65 million	$1.32 million
5/12/2025	Q1 2025	RLMD Relmada Therapeutics	-$0.31	-$0.58	-$0.27	-$0.58	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ENSC Ensysce Biosciences	N/A	N/A	N/A	N/A	N/A
FNCH Finch Therapeutics Group	N/A	N/A	N/A	N/A	N/A
RLMD Relmada Therapeutics	N/A	N/A	N/A	N/A	N/A
RVPH Reviva Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ENSC Ensysce Biosciences	N/A	2.50	2.50
FNCH Finch Therapeutics Group	N/A	3.87	3.87
RLMD Relmada Therapeutics	N/A	5.29	5.29
RVPH Reviva Pharmaceuticals	N/A	0.54	0.54

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ENSC Ensysce Biosciences	5.63%
FNCH Finch Therapeutics Group	21.77%
RLMD Relmada Therapeutics	45.24%
RVPH Reviva Pharmaceuticals	63.18%

Insider Ownership

Company	Insider Ownership
ENSC Ensysce Biosciences	7.90%
FNCH Finch Therapeutics Group	44.90%
RLMD Relmada Therapeutics	20.70%
RVPH Reviva Pharmaceuticals	27.18%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ENSC Ensysce Biosciences	10	2.37 million	2.18 million	Not Optionable
FNCH Finch Therapeutics Group	190	1.61 million	885,000	No Data
RLMD Relmada Therapeutics	10	33.19 million	26.32 million	Optionable
RVPH Reviva Pharmaceuticals	5	48.00 million	34.96 million	Optionable

ENSC, RLMD, RVPH, and FNCH Headlines

Recent News About These Companies

Reviva Pharmaceuticals Holdings, Inc. (RVPHW) - Yahoo Finance

July 5, 2025 | finance.yahoo.com

Reviva Pharmaceuticals Holdings, Inc. (RVPH) - Investing.com

June 29, 2025 | investing.com

Reviva Dives on Stock Offering

June 26, 2025 | baystreet.ca

Reviva Pharmaceuticals Holdings, Inc. Announces Pricing of $10 Million Public Offering

June 26, 2025 | globenewswire.com

Reviva Pharmaceuticals stock falls after announcing public offering

June 25, 2025 | za.investing.com

Reviva Pharmaceuticals Holdings, Inc. Announces Proposed Public Offering

June 25, 2025 | globenewswire.com

RVPH: Open Label Extension Results & Key Opinion Leader Discussion

June 5, 2025 | finance.yahoo.com

Reviva to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference

June 5, 2025 | globenewswire.com

Reviva Announces Positive Full Dataset for 1-Year Phase 3 RECOVER Open Label Extension Study Evaluating Brilaroxazine in Schizophrenia

June 2, 2025 | globenewswire.com

Reviva to Participate in Upcoming Investor Conferences in May 2025

May 20, 2025 | santelog.comS

Reviva Reports First Quarter 2025 Financial Results and Recent Business Highlights

May 15, 2025 | globenewswire.com

Reviva to Participate in the A.G.P. Healthcare Company Showcase

May 13, 2025 | finance.yahoo.com

Analysts Have Conflicting Sentiments on These Healthcare Companies: Icon (ICLR), Reviva Pharmaceuticals Holdings (RVPH) and SurModics (SRDX)

May 4, 2025 | theglobeandmail.com

Reviva to Participate in the Citizens Life Sciences Conference

April 29, 2025 | finance.yahoo.com

RVPH: M&A Deals Highlight Brilaroxazine Value

April 7, 2025 | finance.yahoo.com

Roth MKM Reaffirms Their Buy Rating on Reviva Pharmaceuticals Holdings (RVPH)

April 5, 2025 | markets.businessinsider.com

Reviva Reports Full Year 2024 Financial Results and Recent Business Highlights

March 31, 2025 | markets.businessinsider.com

Reviva to Present Brilaroxazine Topline Data for Long-Term OLE Portion of RECOVER Study in Schizophrenia at 2025 SIRS Congress

March 30, 2025 | globenewswire.com

Why Reviva Pharmaceuticals Holdings, Inc.’s (RVPH) Stock Is Down 10.61%

March 7, 2025 | aaii.comA

Unusually active option classes on open February 12th

February 12, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ENSC, RLMD, RVPH, and FNCH Company Descriptions

Ensysce Biosciences NASDAQ:ENSC

$2.13 -0.03 (-1.39%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$2.12 -0.01 (-0.47%)

As of 07/18/2025 07:50 PM Eastern

Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance (MPAR) platform, an over-dose protection opioid prodrug technology. The company is developing PF614, a TAAP oxycodone prodrug candidate for the treatment of acute or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat for overdose protection against excessive oral ingestion, as well as an oral and inhalation drug product of nafamostat for use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. It is also developing PF614, an extended-release oxycodone-derivative that releases clinically effective oxycodone; PF329 for pain with abuse protection; PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for ADHD; and PF9001 to treat Opioid use disorder. The company was founded in 2003 and is based in La Jolla, California.

Finch Therapeutics Group NASDAQ:FNCH

$12.50 0.00 (0.00%)

As of 07/18/2025 01:37 PM Eastern

Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company develops FIN-211, a microbiome candidate designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524 for the prevention, diagnosis, theragnosis or treatment of diseases in humans, including ulcerative colitis; FIN-525 for the treatment of Crohn's disease; and other microbiome product candidates. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; and license agreements with Skysong Innovations LLC, OpenBiome, Arizona State University, and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Boston, Massachusetts.

Relmada Therapeutics NASDAQ:RLMD

$0.58 -0.02 (-3.04%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$0.57 0.00 (-0.69%)

As of 07/18/2025 07:08 PM Eastern

Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system diseases (CNS) and other disorders in the United States. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a N-methyl-D-aspartate receptor antagonist which is in phase 3 clinical trial for the adjunctive or monotherapy treatment of major depressive disorder. The company is headquartered in Coral Gables, Florida.

Reviva Pharmaceuticals NASDAQ:RVPH

$0.40 -0.01 (-1.51%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$0.40 +0.00 (+0.48%)

As of 07/18/2025 07:47 PM Eastern

Reviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis. It is also developing RP1208 for the treatment of depression and obesity. Reviva Pharmaceuticals Holdings, Inc. was founded in 2018 and is headquartered in Cupertino, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time